Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment | Zendy

John D. Cleary | Zendy; Guillermo GarcíaEffrón | Zendy; Stanley W. Chapman | Zendy; David S. Perlin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

Author(s) -

John D. Cleary,

Guillermo GarcíaEffrón,

Stanley W. Chapman,

David S. Perlin

Publication year - 2008

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01568-07

Subject(s) - caspofungin , candida glabrata , microbiology and biotechnology , mutation , biology , mycosis , micafungin , echinocandin , fungemia , voriconazole , antifungal , medicine , fluconazole , genetics , gene , immunology

We describe a case of recurringCandida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research